E. Rance, Rôle de la structure du génome viral sur la réplication du virus de l'hépatite C. Thèse Dr Univ Montr, 1866.

N. Gossens and F. Negro, Nouveaux traitements de l'hépatite C : quelles cibles, quel calendrier, Rev Med Suisse, issue.7, pp.1683-1691, 2011.

M. Faculté-de-médecine-pierre and . Curie, Virus de l'hépatite C. 2015 *cited 2015 Feb 16+; Available from

J. Duclos-vallée, M. Tateo, and E. Teicher, Expérience de la Transplantation Hépatique chez les Patients Infectés par le VIH: Résultats à partir d'une Cohorte Monocentrique > 100 patients *Internet+, 2011.

A. Slim, Virus de l'hépatite C: Aspects virologiques *Internet+, 2014.

A. Grakoui, C. Wychowski, C. Lin, S. Feinstone, and C. Rice, Expression and identification of hepatitis C virus polyprotein cleavage products, J Virol, vol.67, issue.3, pp.1385-95, 1993.

A. Boivin, Assemblage in vitro de la nucléocapside du virus de l'hépatite C, 2006.

M. Laboratoire-de, . Fondamentale, and . Pathogénicité, Replication of Hepatitis C Virus (HCV)

D. Quinkert, R. Bartenschlager, and V. Lohmann, Quantitative Analysis of the Hepatitis C Virus Replication Complex, Journal of Virology, vol.79, issue.21, pp.13594-605, 2005.
DOI : 10.1128/JVI.79.21.13594-13605.2005

J. Pawlotsky, Hepatitis C virus genetic variability: pathogenic and clinical implications, Clinics in Liver Disease, vol.7, issue.1, pp.45-66, 2003.
DOI : 10.1016/S1089-3261(02)00065-X

C. Gaudy and A. Goudeau, The genetic diversity of hepatitis C virus and its implication for pathogenesis and resistance to treatment, Virologie, vol.9, issue.5, pp.343-55, 2005.

D. Smith, J. Bukh, C. Kuiken, A. Muerhoff, C. Rice et al., Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource, Hepatology, vol.28, issue.244, pp.318-345, 2014.
DOI : 10.1002/hep.26744

H. Autorité-de-santé, La HAS définit la place des nouveaux traitements de l'hépatite C, 2014.

C. Meffre, L. Strat, Y. Delarocque-astagneau, E. Dubois, F. Antona et al., Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: Social factors are important predictors after adjusting for known risk factors, Journal of Medical Virology, vol.15, issue.4, pp.546-55, 2010.
DOI : 10.1002/jmv.21734

D. Centers, . Control, and . Prevention, Geographic prevalence of hepatitis C virus infection

H. Autorité-de-santé, Stratégies de dépistage biologique des hépatites virales B et C, 2011.

M. Bernard-requin, SIDA et transfusion sanguine ou l'affaire du sang contamin??. Les difficiles qualifications p??nales, M??decine et Maladies Infectieuses, vol.28, issue.1, pp.15-23, 1998.
DOI : 10.1016/S0399-077X(98)80032-2

H. Autorité-de-santé, Guide -Affection de longue durée -Hépatite Chronique C, 2006.

A. Humar, M. Morris, E. Blumberg, R. Freeman, J. Preiksaitis et al., Nucleic Acid Testing (NAT) of Organ Donors: Is the ???Best??? Test the Right Test? A Consensus Conference Report, American Journal of Transplantation, vol.9, issue.RR-1, pp.889-99, 2010.
DOI : 10.1111/j.1600-6143.2009.02992.x

. Ministère-de-l-'enseignement-supérieur-et-de-la-recherche, Ministère de la santé et des sports Valeurs biologiques usuelles, 2009.

D. Dhumeaux and C. Aknike, Prise en charge des personnes infectées par les virus de l'hépatite B ou de l'hépatite C, 2014.

H. Autorité-de-santé, Critères diagnostiques et bilan initial de la cirrhose non compliquée, 2008.

I. Shimizu, N. Shimamoto, and K. Saiki, Stages of hepatic fibrosis in chronic hepatitis according to the five stages (0-4) of the METAVIR scoring system, 1994.

P. Cacoub, Les manifestations extra-hépatiques au cours de l'infection par le virus de l'hépatite C, 2007.

D. Martino, V. Rufat, P. Boyer, N. , R. P. Degos et al., The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study, Hepatology, vol.34, issue.6, pp.1193-1202, 2001.
DOI : 10.1053/jhep.2001.29201

V. Laurent, F. Legou, M. Pernin, A. Oliver, F. Jausset et al., Chapitre 7 -Aspects postthérapeutiques des carcinomes hépatocellulaires, Imagerie Post-Thérapeutique en Oncologie [Internet], p.2014, 2015.

T. Asselah, M. Martinot, and N. Boyer, Variabilité génétique du virus de l'hépatite C : implications cliniques, p.98403, 2008.

T. Asselah, Hépatite chronique C : Les stratégies thérapeutiques actuelles, J SIDA, issue.199, pp.13-19, 2007.

. Réseau-hépatites-de-basse-normandie, Historique du Virus de l'hépatite C et sa prise en charge, 2009.

A. European-medicines, Résumé des caractéristiques du produit du peginterféron alpha-2a (PEGASYS®), p.2013, 2015.

G. Perlemuter and L. Perlemuter, Guide de thérapeutique 2015

T. Asselah, Y. Benhamou, and P. Marcellin, Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int, pp.57-67, 2009.

. Medscape, Hépatite C : arrêt de la commercialisation du télaprévir le 30 avril, 2015.

. Vidal and O. Monographie-de, Available from: https, 2015.

A. European-medicines, Résumé des caractéristiques du produit du siméprévir (OLYSIO®), p.2014, 2015.

A. European-medicines, Etude structurale et fonctionnelle de NS5B, l'ARN-polymérase du virus de l'hépatite C, par spectroscopie de résonance magnétique nucléaire, anx_129304_fr.pdf 52. European Medicines Agency, pp.2014-2014, 2014.

M. Sofia, Beyond sofosbuvir: What opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?, Antiviral Research, vol.107, pp.119-143, 2014.
DOI : 10.1016/j.antiviral.2014.04.008

H. Autorité-de-santé and . Sofosbuvir, Avis de la commission de transparence, 2014.

. Vidal, Monographie de INCIVO®, 2015.

. Vidal, INCIVO (télaprévir) : arrêt de commercialisation prévu le, 2015.

E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-torres, T. Hassanein et al., Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, New England Journal of Medicine, vol.368, issue.20, pp.1878-87, 2013.
DOI : 10.1056/NEJMoa1214853

. Chemspider, Masse molaire du sofosbuvir, 2014.

A. Cha and A. Budovich, Sofosbuvir: A New Oral Once-Daily Agent for The Treatment of Hepatitis C Virus Infection, Pharm Ther, vol.39, issue.5, pp.345-52, 2014.

V. Dictionnaire, Sovaldi 400 mg cp pellic, 2014.

A. European-medicines, Résumé des caractéristiques du produit du sofosbuvir (SOVALDI®), p.2014, 2014.

E. Murakami, T. Tolstykh, H. Bao, C. Niu, H. Steuer et al., Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977, Journal of Biological Chemistry, vol.285, issue.45, pp.34337-34384, 2010.
DOI : 10.1074/jbc.M110.161802

M. Sofia, D. Bao, W. Chang, J. Du, D. Nagarathnam et al., -methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus, Journal of Medicinal Chemistry, vol.53, issue.19, pp.7202-7220, 2010.
DOI : 10.1021/jm100863x

URL : https://hal.archives-ouvertes.fr/hal-00732567

T. Reddy, L. Chan, N. Turcotte, M. Proulx, O. Pereira et al., Further SAR studies on novel small molecule inhibitors of the hepatitis C (HCV) NS5B polymerase, Bioorganic & Medicinal Chemistry Letters, vol.13, issue.19, pp.3341-3345, 2003.
DOI : 10.1016/S0960-894X(03)00670-X

J. Pawlotsky and C. Hépatite, Résistance aux traitements [Internet]. 2015 Available from

A. Biology, Biology A2 revision OCR [Internet], 2014.

A. Lam, E. Murakami, C. Espiritu, H. Steuer, C. Niu et al., PSI-7851, a Pronucleotide of ??-D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication, Antimicrobial Agents and Chemotherapy, vol.54, issue.8, pp.3187-96, 2010.
DOI : 10.1128/AAC.00399-10

M. Rodriguez-torres, E. Lawitz, K. Kowdley, D. Nelson, E. Dejesus et al., Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-na??ve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial, Journal of Hepatology, vol.58, issue.4, pp.663-671, 2013.
DOI : 10.1016/j.jhep.2012.11.018

. Autorité-de-la-concurrence, Fixation des prix des médicaments, 2013.

H. Autorité-de-santé, Avis de la CT du 14 mai 2014, 2014.

A. Hill, S. Khoo, and B. Simmons, Minimum costs to produce Hepatitis C Direct Acting Antivirals, 2015.

. Huffingtonpost and . Sovaldi, hépatite C peut coûter 705 euros en Inde et 41.000 euros en France [Internet] Available from: http://www.huffingtonpost.frsovaldi-prix-cout-france-hepatite-c_n_6190642.html 88. Food and Drug Administration. Sofosbuvir's cost, 2013.

A. Mangia and V. Piazzolla, Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies, Digestive and Liver Disease, vol.46, issue.5, pp.179-85, 2014.
DOI : 10.1016/j.dld.2014.09.026

S. Zeuzem, G. M. Dusheiko, . Salupere, . Riina, A. Mangia et al., Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients With HCV Genotype 2 or 3: the VALENCE Trial. 64rd Annu Meet Am Assoc Study Liver Dis Wash DC [Internet], 2013.

M. Sulkowski and L. Rodriguez-torres, All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV

D. Food and . Administration, Sofosbuvir For Treatment of Chronic Hepatitis C Infection Available from: http://www.fda.gov, 2013.

H. Autorité-de-santé and . Ribavirine, Avis de la commission de transparence Available from, 2010.

E. Lawitz, D. Wyles, and M. Davis, Treatment With Sofosbuvir + Peginterferon + Ribavirin for 12 Weeks Achieves 90% SVR12 in Treatment-Naïve Genotype 1, 4, 5, and 6 HCV-Infected Patients: The NEUTRINO Study, EASL 48th Annual Meeting, 2013.

L. Zhang, Q. Lu, Z. Yang, X. Wang, L. Cai et al., Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: A meta-analysis, Human Immunology, vol.75, issue.12, pp.1268-75, 2014.
DOI : 10.1016/j.humimm.2014.09.005

. Lawitz, . Wyles, . David, and A. Mangia, Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection, New England Journal of Medicine, vol.368, issue.20, pp.1878-87, 2013.
DOI : 10.1056/NEJMoa1214853

S. Xu, S. Rajyaguru, S. Chiu, C. Hebner, E. Svarovskaia et al., Sofosbuvir Selects the NS5B S282T Mutation In Vitro in Genotype 1-6 Replicons and Is Not Cross-Resistant to Resistance-Associated Variants Selected by Other Classes of Antiviral Inhibitors. 64rd Annu Meet Am Assoc Study Liver Dis Wash DC, 2013.

I. Jacobson, R. Ghalib, and M. Rodriguez-torres, SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and noncirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. 64rd Annu Meet Am Assoc Study Liver Dis Wash DC, 2013.

E. Lawitz, R. Ghalib, and M. Rodriguez-torres, Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype-1 prior null-responder / treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2) Int Liver Congr 2014 49th Annu Meet Eur Assoc Study Liver Lond, 2014.

M. Sulkowski, D. Gardiner, M. Rodriguez-torres, K. Reddy, T. Hassanein et al., Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection, New England Journal of Medicine, vol.370, issue.3, pp.211-232, 2014.
DOI : 10.1056/NEJMoa1306218

D. Nelson, J. Feld, and K. Kowdley, All Oral Therapy With Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment-Experienced Genotype 2/3 HCV-Infected Patients: Results of the Phase 3 FUSION Trial, p.2013, 2014.

G. Sulkowski and . Rodriguez-torres, Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) In Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) Or Boceprevir (BOC) Poster Abstr Sess Clin Trials IDWeek 2013 San Franc [Internet]. 2013; Available from: https, 2013.

P. Ruane, D. Ain, R. Stryker, R. Meshrekey, M. Soliman et al., Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry, Journal of Hepatology, vol.62, issue.5, 2014.
DOI : 10.1016/j.jhep.2014.10.044

E. Lawitz, F. Poordad, and D. Brainard, Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment-Experienced Patients with and without Compensated Cirrhosis: Results from the LONESTAR-2 Study. 64rd Annu Meet Am Assoc Study Liver Dis Wash DC [Internet], 2013.

W. Berrebi, Diagnostics et thérapeutique de poche: Guide pratique du symptôme à la prescription, Armando Editore, 2009.

P. Morlat, A. Blanc, F. Bourdillon, and F. Brun-vezinet, Prise en charge médicale des personnes vivant avec le VIH, actualisations 2014 du rapport 2013

C. Chu and S. Lee, Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment, Journal of Gastroenterology and Hepatology, vol.46, issue.4, pp.512-532, 2008.
DOI : 10.1097/01.meg.0000224479.97169.e8

C. Ferri, Mixed cryoglobulinemia, Orphanet Journal of Rare Diseases, vol.3, issue.1, p.25, 2008.
DOI : 10.1186/1750-1172-3-25

J. Jeannel, D. Bonnet, P. Cacoub, S. Pol, D. Canioni et al., ??valuation de l???efficacit?? virologique et de la tol??rance du traitement antiviral chez les patients porteurs d???une h??patite C chronique, associ??e ?? un lymphome B non hodgkinien??: ??tude cas-t??moins ANRS HC13??lympho-C, La Revue de M??decine Interne, vol.35, issue.2, pp.127-135, 2014.
DOI : 10.1016/j.revmed.2014.10.214

J. Gisbert, L. García-buey, J. Pajares, and R. Moreno-otero, Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection, Alimentary Pharmacology and Therapeutics, vol.93, issue.3, pp.653-62, 2005.
DOI : 10.1046/j.1365-2141.1996.6912313.x

H. Autorité-de-santé, Prise en charge de l'hépatite C par les médicaments anti-viraux à action directe (AAD) 2014 [cited 2015 Feb 13]; Available from

C. Lange and C. Sarrazin, Hepatitis C : New Drugs. hcvets *Internet+, 2012.

C. Stedman, Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential, Therapeutic Advances in Gastroenterology, vol.58, issue.567, pp.131-171, 2014.
DOI : 10.1056/NEJMoa1010494

A. Alberti and S. Piovesan, The evolution of the therapeutic strategy in hepatitis C: Features of sofosbuvir and indications, Digestive and Liver Disease, vol.46, issue.5, pp.174-182, 2014.
DOI : 10.1016/j.dld.2014.09.028

M. Bourlière, V. Oules, C. Ansaldi, X. Adhoute, and P. Castellani, Sofosbuvir as backbone of interferon free treatments, Digestive and Liver Disease, vol.46, issue.5, pp.212-232, 2014.
DOI : 10.1016/j.dld.2014.09.024

A. Lam, C. Espiritu, S. Bansal, H. Steuer, C. Niu et al., Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus, Antimicrobial Agents and Chemotherapy, vol.56, issue.6, pp.3359-68, 2012.
DOI : 10.1128/AAC.00054-12

. Organisation-mondiale-de-la-santé, Safety Monitoring of Medicinal Products: Guidelines for Setting Up and Running a Pharmacovigilance Centre, 2000.

G. Sciences and . Sovaldi, Adverse Reactions from Clinical Trials Experience, 2014.

M. Sulkowski, M. Shiffman, N. Afdhal, K. Reddy, J. Mccone et al., Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate, Gastroenterology, vol.139, issue.5, pp.1602-1613, 1611.
DOI : 10.1053/j.gastro.2010.07.059

P. Van-der-linden, La physiologie de l'anémie isovolémique aiguë : Questions pratiques Anesth Conférences Sci [Internet] Available from, 2004.

H. Autorité-de-santé and . Viraferonpeg, Avis de la commission de transparence Available from: http://www.hassante.fr/portail/upload/docs/application, p.31440, 2011.

D. Balayssac, N. Authier, and F. Coudoré, Interactions médicamenteuses liées à une inhibition de la P-glycoprotéine, 2004.

G. Keating and . Sofosbuvir, Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C, Drugs, vol.58, issue.4 Suppl, pp.1127-1173, 2014.
DOI : 10.1007/s40265-014-0247-z

M. Puoti, C. Panzeri, R. Rossotti, and C. Baiguera, Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs, Digestive and Liver Disease, vol.46, issue.5, pp.206-217, 2014.
DOI : 10.1016/j.dld.2014.09.027

C. Research and . De, Drug Safety and Availability -FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug, p.2015, 2015.

V. Dictionnaire, Antiviraux d'action directe contre l'hépatite C : éviter la prescription conjointe d'amiodarone, 2015.